

CURRICULUM VITAE

I.

a	<u>Name</u>	Olayinka Adejoke <u>Kotila</u> (nee Odunsi)
b	Date of birth	3 August, 1975
c	<u>Department</u>	Pharmaceutical Chemistry
d	<u>Faculty</u>	Pharmacy

II.

a	First Academic Appointment	Lecturer II	21 April, 2008
b	Present Post (with date)	Lecturer I	01 Oct., 2014

III. **University Education (with dates)**

a	University of Ibadan, Ibadan	1993 - 1999
b	University of Ibadan, Ibadan	2004 - 2006
c	University of Ibadan, Ibadan	2008 - 2018

IV. **Academic Qualifications (with dates and granting bodies)**

a	Bachelor of Pharmacy (B. Pharm), University of Ibadan	Feb. 1999
b	M.Sc. (Pharmaceutical Chemistry), University of Ibadan	Nov. 2006
c	Ph.D (Pharmacokinetics and Bioavailability Studies), University of Ibadan	June 2018

V. **Professional Qualifications and Diplomas (with dates)**

1.	Certificate of Participation in Winter Institute of Statistical Genetics, Abu Dhabi, UAE	20-24 January, 2019
2.	Certificate of Participation in The Role of Pharmacogenetics in Drug Discovery, University of Ibadan, Nigeria	March, 2015
3.	Certificate of Completion of Diagnostic Molecular Pathology Workshop, University of Ibadan, Nigeria	14-17 April, 2014
4.	Certificate of Completion of Pharmacometrics Course, Dar es Salaam, Tanzania	5-8 Aug., 2013
5.	Certificate of Completion on Data Analysis and Manuscript Writing Workshop, University of Ibadan, Nigeria	7-14 July, 2013
6.	Certificate of Participation in CIPZ Workshop on Principles and Application of PCR Techniques, Ibadan, Nigeria	10-14 June, 2013

- | | | |
|-----|--|------------------|
| 7. | Certificate of Completion on Biomedical Informatics, University of Ibadan, Nigeria | 20-22 Aug., 2012 |
| 8. | Certificate of Attendance of Training on Mentorship (jointly organised by MEPIN and Northwestern University, Chicago, USA) | 27-29 Aug., 2012 |
| 9. | Certificate of Attendance of Genomic Epidemiology In Africa, Blantyre, Malawi | 6-11 May, 2012 |
| 10. | Registered Pharmacist - Pharmaceutical Society of Nigeria (MPSN) | Feb., 1999 |

VI. Scholarships, Fellowships and Awards (with date)

- | | | |
|-----|--|------------------------|
| 1. | African Society of Human Genetics (AfSHG) and H3Africa Consortium Bursary Award (Won Best Oral Presentation at the conference) | 2018 |
| 2. | Thomas-Bassir Biomedical Foundation Small Research Grants | 2017 |
| 3. | Fogarty International Center (FIC)-NIH Grant for Addressing NCDs in Nigeria through Enhanced International Partnership and Interdisciplinary Research Training in University of Ibadan.
Grant Number: 1D71TW010876-01 | 2017 |
| 4. | Tertiary Education Trust Fund (TETFUND) | 2014 |
| 5. | NIH D43 Re-entry Grant Award | 2013 |
| 6. | Novartis Scholarship Award – Pharmacometrics Course in Tanzania | 2013 |
| 7. | Wellcome Trust Bursary Award | 2012 |
| 8. | MEPIN Year 02 Seed Award (Award number R24TW008878 from the Fogarty International Center) | 2012 |
| 9. | Global Health Initiative Fellowship Award, University of Chicago, USA | 2010 & 2011
(twice) |
| 10. | NIH Training award on Clinical Research, University of Ibadan, Nigeria | 2010 |
| 11. | MacArthur Foundation Multidisciplinary Research Grant (Co-Investigator) | Oct. 2009 |

VII. Honours, Distinctions and Membership of Learned Societies

Member, Pharmaceutical Society of Nigeria (MPSN)

Member, Nigerian Association of Pharmacists in Academia (NAPA)

Member, International Society for Study of Xenobiotics (ISSX).

VIII Details of Teaching/Work Experience

- a) Courses taught at undergraduate level:
- Physical Pharmaceutical Chemistry
 - Organic Pharmaceutical Chemistry

- Inorganic Pharmaceutical Chemistry
 - Medicinal Chemistry
 - Biopharmaceutical Methods
 - Pharmacokinetics
 - Pharmaceutical Analysis and Quality Assurance
 - Drug Design & Development
 - Drugs and Mankind (General Studies Programme course)
- b) Undergraduate project supervision
- Co-supervision - 3
 - Sole supervision - 9
- c) Courses taught at postgraduate level:
- Bioanalytical and Biopharmaceutical Methods of Drug Analysis
 - Drug metabolism, Pharmacogenetics and toxicology
- d) Administrative experience
- | | | |
|-------|---|----------------|
| i. | Member, Faculty Curriculum Committee | 2017 till date |
| ii. | Coordinator, departmental undergraduate programs | 2017 till date |
| iii. | Member, NAPA Executive Committee | 2014 till date |
| iv. | Member, UI/UCH Institutional Review Committee, UI, Nigeria. | 2014 till date |
| v. | Member, Faculty Alumni Executive Committee | 2013 till date |
| vi. | Member, Faculty Dress Code Committee | 2013 till date |
| vii. | Departmental Class Coordinator for 500 Level | 2012 till date |
| viii. | Member, CDDDP Implementation committee | 2011 - 2017 |
| ix. | Member, Computer committee | 2010 - 2016 |
| x. | Member, Induction committee | 2008 – 2014 |
| xi. | Rapporteur, UI @ 60 Exhibition | 2008 |

IX. **Research**

- (a) Completed Research
- Spectrophotometric analysis of Lumefantrine-Chloranilic acid charge-transfer complex.
 - Determination of physicochemical properties of Lumefantrine.
 - Simultaneous spectrophotometric analysis of trimethoprim and sulphamethoxazole via charge-transfer complexation reaction with chloranilic acid.
 - Epidemiological survey on hypersensitivity to sulphonamides in over a thousand (>1,000) respondents.
 - Genotyping of the N-acetyltransferase enzyme 2 (NAT2) in over five hundred (>500) Nigerians including one hundred (100) HIV-positive patients.
 - Phenotype analysis of NAT2 in over three hundred (>300) Nigerian volunteers using two probe drugs: dapsone and caffeine
 - Pharmacokinetics of dapsone, a NAT2 substrate drug in Nigerians.

(b) Research in-progress

- Epidemiological genotyping of detoxifying genes (GSTT, GSTP, GSTM) and CYP2C9 drug metabolizing enzyme in Nigerians
- Protocol development for genotype-phenotype correlation of plasma concentration of dolutegravir in HIV-positive Nigerian patients

Research Support

OA Kotila (Awardee)

2013

NIH D43 Re-entry Grant

This fund enabled me travel to Zimbabwe to acquire skills in use of high-throughput equipment – LC/MS/MS in quantifying drugs in bio-matrices (plasma and urine). This followed my being a recipient of the University of Chicago Global Health Pre-doctoral Fellowship.

Role: Graduate researcher

OA Kotila (Researcher)

2014

TETFUND Academic Staff Training and Development Fund (AST&D)

This fund enabled me travel to a south African country to train in use of liquid chromatography-mass spectrometer (LCMS) for analysis of drugs and metabolites in biological matrices. This is needed for pharmacokinetics studies that I am carrying out to complement pharmacogenetics results already obtained

Role: Graduate researcher

CP Babalola (PI)

2011 - 2016

Centre for Drug Discovery, Development and Production (CDDDP) in University of Ibadan.

The rationale for this project is to establish a Centre that will serve as a platform for training, research and development in the area of drug discovery, development and production (DDDP) to meet the needs of Nigeria and Sub-Saharan Africa. This is needed because access to medicines in Nigeria and Sub-Saharan Africa is currently limited by imports.

Role: Investigator

OA Kotila (Researcher)

2017

Thomas-Bassir Biomedical Foundation Small Research Grants

Many populations have reported on homozygous deletions, leading to loss of activity in the two genes: GSTM1 and GSTT1 and these deletions have been strongly associated with development of solid tumors, including lung, larynx, and bladder cancer, especially when linked with absence of other enzymes or prolonged exposure to carcinogens, such as tobacco. Studies have shown the interrelated effects of NAT2 and GSTs on induction of certain cancers due to loss in detoxification activity. This grant will therefore enable me investigate if such relatedness exists in Nigerians.

Role: Early researcher

X. **Publications**

Articles that have already appeared in Learned Journals:

Kotila O.A, Fawole O, Olopade O.I, Ayede A.I, Falusi A.G, Babalola C.P. (2019) N-acetyltransferase II Enzyme Genotype-Phenotype Discordances in both HIV-negative and HIV-positive Nigerians. *Pharmacogenetics and Genomics (in press)*.

Nwogu JN, **Kotila OA**, Obaro M, Babalola CP (2017). Effects of Antacids on The Pharmacokinetics and Electrocardiographic Dynamics of Lumefantrine In Healthy Volunteers.

Adegoke, A.O., Babalola, C.P., **Kotila, O.A.** and Obuebhor, O. (2017). Simultaneous Spectrophotometric Determination of Trimethoprim and Sulphamethoxazole following Charge-transfer Complexation with Chloranilic acid, Arabian Journal of Chemistry 10 (supplement 2), S3848-3860.

Akpan M.R, **Kotila O.A.**, Akpa O.M, Fawole O, Falusi A.G, Babalola C.P. (2015). Self-reported Sulphonamide Hypersensitivity Reactions in Adults Living in Ibadan, Nigeria: A Cross-sectional Community-based Study. Nigerian Medical Journal Vol. 56 No 6, 404-410

Babalola C.P, Oluwalana I, **Kotila O.A.**, Adegoke O.A, Kolade Y.T, Ameh S.J. (2014). A Novel Derivatization Ultraviolet Spectrophotometric Method for the Determination of Dihydroartemisinin using p-Nitroaniline. Tropical Journal of Pharmaceutical Research Vol. 13 No.1, 127-133.

Babalola C.P, Kolade Y.T, Adeyemo M.A, **Kotila O.A.**, Ameh S.J, Adelokun T.A, Adewuyi S, Kwasi G.N, Scriba G.K. (2014): Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine. Global Journal of Medical research: B Pharma, Drug Discovery, Toxicology and Medicine. Vol 14. No1, 4-10

Kotila O.A., Olaniyi O, Adegoke O.A, Babalola C.P. (2013): Experimental Determination of the Physicochemical Properties of Lumefantrine. African Journal of Medicine and Medical Sciences Vol 42. No.3 , 209-214

Babalola C.P, Kanu D.N, Okafor G.O, Wumi A, Ajayi O, **Kotila O.A.**, Farombi E.O. (2013): Toxicological Effect of Sub-therapeutic, Therapeutic and Overdose Regimens of Halofantrine Hydrochloride on Male Albino Rats. Pharmacologia Vol. 4 No.3, 180-185

Babalola C.P, Ajayi O, **Kotila O.A.**, Ameh S. (2011): In-Vitro Interaction Studies of Lumefantrine With Antacids. International Journal of Comprehensive Pharmacy. (IJCP) Vol. 3 No.1, 1-4

Babalola C.P, **Kotila O.A.**, Dixon P.A.F, Oyewo A.E. (2011): Disposition of quinine and its major metabolite, 3-hydroxyquinine in patients with liver disease. Research in Pharmaceutical Biotechnology Vol .3 No.3, 25-29.

Babalola C.P, Awolaye S.A, Akinyemi J.O, **Kotila O.A.** (2011): Evaluation of prescription pattern in Southwest Nigeria. Journal of Public Health and Epidemiology Vol. 3 No. 3, 94-98.

Adegoke O.A, Babalola C.P, Isaac P.O.K, **Kotila O.A.** (2011): Spectrophotometric studies of the charge-transfer complexation between Lumefantrine and Chloranilic acid in acetonitrile. Acta Pharmaceutica Scientia Vol.53,135-149

Babalola C.P, Olori E.O, **Kotila O.A.**, Falade O, Kolade Y.T, Sylva B.O. (2009): Effect of Artesunate on the Urinary Excretion of Cloxacillin in Healthy Subjects. Nigerian Journal of Pharmaceutical Research Vol. 7 No.1, 29-36

Published abstracts

Kotila O.A., Fawole O, Olopade O.I, Ayede A.I, Falusi A.G, Babalola C.P. N-acetyltransferase II discordant genotype-phenotype relationship in HIV-positive and HIV-negative Nigerians.

Joint 11th Conference of African Society of Human Genetics & 12th H3Africa Consortium Meeting, 16-23 September 2018 - Kigali Convention Centre. (**Won Best Oral Presentation**).

Chiudo E.G, **Kotila O.A**, Babalola C.P. Pharmaceutical non-equivalence of cyclophosphamide generic brands in southwest Nigeria – a lurking danger. Abstract Book AORTIC Conference 2017, Kigali, Rwanda, 7-10 November 2017, Abstract No. 429.

Kotila O.A, Fawole O, Ayede A.I, Olopade O.I, Falusi A.G, Babalola C.P. NAT2 haplotype distribution in a Nigerian population. 5th FIP Pharmaceutical Sciences World Congress 2014, Melbourne, Australia, 13th - 16th April, 2014, Abstract No. PF 027.

Akpan M.R, **Kotila O.A**, Akpa O.M, Ayede A.I, Fawole O., Olopade O.I, Falusi A.G, Babalola C.P. Self-reported adverse reactions to sulphonamides in Ibadan, Oyo State, Nigeria. 86th National Conference of the Pharmaceutical Society of Nigeria, 4th - 8th November, 2013.

Kotila O.A, Babalola C.P, Fawole O., Falusi A.G, Das S., Olopade O.I (2012). Genotype analysis of NAT2 gene in HIV-positive Nigerians. 3rd Unibadan Conference of Biomedical Research, University of Ibadan, 24th - 27th July, 2012, Abstract No. OPA18, Page 20

Babalola C.P, Ekom M, **Kotila O.A**, Fawole O, Irabor C, Falusi A.G, and Adewole I.F. Prevalence of sulphonamides adverse reactions in HIV positive patients attending PEPFAR clinic, University College Hospital, Ibadan, South west, Nigeria. Abstract Book AORTIC Conference 2011, Cairo, Egypt, 30 November-02 December 2011, Abstract No. 348

Babalola C.P, Olori E.O, Falade O.B, Kolade Y.T, **Kotila O.A**, Sylva B.O (2008) 'Effect of artesunate on the urinary excretion of cloxacillin after co-administration of ampicillin-cloxacillin combination with artesunate in healthy subjects'. Annual Conference & Scientific Meeting of Nigerian Association of Pharmacists in Academia, Obafemi Awolowo University, Ile-Ife; 30th July-2nd Aug., 2008, Page 28

Babalola C.P, Adegbola O.J, **Kotila O.A** (2008) 'Drug-Drug interactions between amoxicillin and dihydroartemisinin'. Annual Conference & Scientific Meeting of Nigerian Association of Pharmacists in Academia, Obafemi Awolowo University, Ile-Ife; 30th July-2nd Aug., 2008, Page 24

XII. **Major Conferences/Workshops Attended**

July, 2012. 3rd Unibadan Conference of Biomedical Research, University of Ibadan, Ibadan, Oyo State

Paper presented: Genotype analysis of NAT2 gene in HIV-positive Nigerians

Oct., 2013. International conference on Medicine Regulation on Claims: 'From Concept to Launch', organized by Centre for Drug Discovery, Development and Production (CDDDP) in conjunction with Reckitt Benckiser, UK at University of Ibadan.

Nov., 2013. 86th National Conference of the Pharmaceutical Society of Nigeria, Ilorin, Kwara State

Paper presented: Self-reported adverse reactions to sulphonamides in Ibadan, Oyo State, Nigeria.

Mar., 2015. Joint CDDDP-African Institute for Biomedical Research and Training (AiBST) Zimbabwe, Training Workshop on The Role of Pharmacogenetics in Drug Discovery, University of Ibadan, Nigeria

Aug., 2015. 13th National Scientific Conference of Nigeria Association of Pharmacists in

Academia (NAPA), Ibadan, Oyo State

Paper presented: N-acetyltransferase II enzyme haplotyping in HIV-positive and healthy Nigerians and its relatedness to sulphonamide hypersensitivity

April, 2016. Chicago-Ibadan Partnership D43 Fogarty Research Training Grant Workshop titled "Enhancing Interdisciplinary Teams: Propelling Research from Theory to Practice" at University of Ibadan/University College Hospital, Ibadan, Nigeria.

Aug., 2017. International Conference on Improving Access To Quality Medicines Through Appropriate Legislations and Policies organized by The Centre for Drug Discovery, Development and Production (CDDDP), University of Ibadan, Nigeria.

Mar., 2018. Non-Communicable Diseases (NCDs) Research in Nigeria: Matching Priorities to Human Capacities organized by Centre for Population and Reproductive Health (CPRH), College of Medicine, University of Ibadan in conjunction with Centre for Global Health, University of Chicago, Chicago, USA.

June, 2018. Ethics and Responsible Conduct of Research organized by Centre for Population and Reproductive Health (CPRH), College of Medicine, University of Ibadan (NIH D71 Planning Grant).

Sept., 2018. Joint 11th Conference of African Society of Human Genetics & 12th H3Africa Consortium Meeting, 16-23 September 2018 - Kigali Convention Centre.

Paper presented: Kotila O.A, Fawole O, Olopade O.I, Ayede A.I, Falusi A.G, Babalola C.P. N-acetyltransferase II discordant genotype-phenotype relationship in HIV-positive and HIV-negative Nigerians. (**Won Best Oral Presentation**).

<https://www.scopus.com/authid/detail.uri?authorId=44861333400>

https://www.researchgate.net/profile/Olayinka_Kotila/publications

<https://www.ncbi.nlm.nih.gov/pubmed/?term=kotila+oa>

https://scholar.google.com/citations?hl=en&user=gEURAxAAAAAJ&scilu=495623730840120576:0,14118006557396389908:0,14737755220833265825:0,15962282511634519086:0&scisig=AMstHGQAAAAAWMJw1eY3f1pSm_dXrhKOYY73yCAQUjm&gmla=AJsNF5s2DsIW51iGhFoOHwIICDB3yBoIByCmMCd_uMBMuj8O7Wo40GbilpxI36eLI9KsY9UOi5Z25TgI8Ac36ZgF10H-2FPVcCVmmd2OmYbDnt-l8b-MY&sciund=13546940879870024136

Signed

OLAYINKA A. KOTILA (B.Pharm., PhD)